286 related articles for article (PubMed ID: 34480575)
1. Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine.
Richmond PC; Hatchuel L; Pacciarini F; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
J Infect Dis; 2021 Nov; 224(10):1699-1706. PubMed ID: 34480575
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Buntinx E; Brochado L; Borja-Tabora C; Yu CY; Alberto ER; Montellano MEB; Carlos JC; Toloza LB; Hites M; Siber G; Clemens R; Ambrosino D; Qin H; Chen HL; Han HH; Hu B; Li P; Baccarini C; Smolenov I
Vaccine; 2023 Mar; 41(11):1875-1884. PubMed ID: 36781334
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
6. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Lopez P; Bravo L; Buntinx E; Borja-Tabora C; Velasquez H; Rodriquez EJ; Rodriguez CA; Carlos J; Montellano MEB; Alberto ER; Salvani-Bautista M; Huang Y; Hu B; Li P; Han HH; Baccarini C; Smolenov I
Hum Vaccin Immunother; 2023 Dec; 19(1):2206359. PubMed ID: 37226504
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
Ambrosino D; Han HH; Hu B; Liang J; Clemens R; Johnson M; Siber G; Goldblatt D
J Infect Dis; 2022 Jan; 225(2):327-331. PubMed ID: 34888662
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Amarilla AA; Modhiran N; Liang B; Li Z; Wijesundara DK; Lackenby JA; Griffin P; Bennet JK; Hensen L; Zhang W; Nguyen THO; Tran MH; Tapley P; Barnes J; Reading PC; Kedzierska K; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
EBioMedicine; 2023 Nov; 97():104842. PubMed ID: 37865043
[TBL] [Abstract][Full Text] [Related]
11. A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.
To A; Wong TAS; Lieberman MM; Thompson K; Ball AH; Pessaint L; Greenhouse J; Daham N; Cook A; Narvaez B; Flinchbaugh Z; Van Ry A; Yalley-Ogunro J; Andersen Elyard H; Lai CY; Donini O; Lehrer AT
ACS Infect Dis; 2022 Apr; 8(4):825-840. PubMed ID: 35263081
[TBL] [Abstract][Full Text] [Related]
12. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
14. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
[TBL] [Abstract][Full Text] [Related]
15. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
16. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
17. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
18. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
20. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
